Elite in Pancreatic Cancer
Check Dr. Brian M. Wolpin's experience treating your condition:
About Dr. Brian M. Wolpin

Brian Wolpin is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Wolpin has been practicing medicine for over 22 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 10 other conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Endoscopy, and Tubal Ligation. He is licensed to treat patients in Massachusetts. Wolpin is currently accepting new patients.

His clinical research consists of co-authoring 203 peer reviewed articles and participating in 14 clinical trials in the past 15 years. In particular, he has co-authored 134 articles and participated in 12 clinical trials in the study of Pancreatic Cancer.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Brian M. Wolpin it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
450 Brookline Ave, Boston, MA 02215
Background & Education
Graduate Institution
Harvard Medical School, 2001
Hematology Oncology
Internal Medicine in MA
Hospital Affiliations
Milford Regional Medical Center
Brigham And Womens Hospital
Dana Farber Cancer Institute
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

BrafPanc: A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E Mutation
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Pancreatic Cancer
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study
Phase II Study of Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
A Single Arm Phase II Trial of Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Phase I/II Trial of OSI-906 in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Ductal Adenocarcinoma of the Pancreas
View 10 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors